GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

MXCT · Mar 31, 2025

MAXCYTE, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001558370-25-007005General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

11.37% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-250.93% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

2.85% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

144.07% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

154.85% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-214.09% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

102.79% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

52.92% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesHistory building
Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20257/8 normalizedLevel 3Dec 31, 20257/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
7.43%
Current
11.37%
Delta
3.94%
Cash Generation Decreased
Previous
-124.29%
Current
-250.93%
Delta
-126.65%
Growth Decreased
Previous
13.94%
Current
2.85%
Delta
-11.09%
Inventory Pressure Increased
Previous
40.13%
Current
144.07%
Delta
103.94%
Margin Increased
Previous
141.92%
Current
154.85%
Delta
12.93%
Profitability Increased
Previous
-230.46%
Current
-214.09%
Delta
16.37%
R And D Intensity Increased
Previous
100.05%
Current
102.79%
Delta
2.73%
Sbc Intensity Decreased
Previous
58.89%
Current
52.92%
Delta
-5.98%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · MXCT Fundamental State →Has State · MAXCYTE, INC. →Transitioned To · MXCT Fundamental State →Transitioned To · MXCT CAPEX_INTENSITY_INCREASED →Transitioned To · MXCT CASH_GENERATION_DECREASED →Transitioned To · MXCT GROWTH_DECREASED →Transitioned To · MXCT INVENTORY_PRESSURE_INCREASED →Transitioned To · MXCT MARGIN_INCREASED →Transitioned To · MXCT PROFITABILITY_INCREASED →Transitioned To · MXCT R_AND_D_INTENSITY_INCREASED →Transitioned To · MXCT SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.